Radiopharmaceutical provider DraxImage has received Food and Drug Administration approval to produce and market a new formulation to prepare a skeletal imaging agent used to demonstrate areas of altered osteogenesis, or bone growth.
Called MDP-25, the kit is a preparation for technetium Tc-99m medronate injection, which is used in applications ranging from metastatic bone disease, Paget’s disease, arthritic disease, and osteomyelitis, according to the Mississauga, Ontario-based firm. Each vial of MDP-25 contains freeze-dried powder that is reconstituted immediately before use with radioactive sodium pertechnetate solution.
The resulting active labeling agent remains stable throughout the 12-hour life of the preparation, and following injection the agent is accumulated and retained by the skeleton for imaging by a gamma camera. DraxImage said it expects to make the MDP-25 imaging kit available through the company and its distribution network during the second quarter.
By AuntMinnie.com staff writers
March 1, 2004
Related Reading
Draxis Q4 and year-end revenues jump, February 6, 2004
Draxis revenues jump, November 6, 2003
Draxis scores patent, October 2, 2003
DraxImage begins Infecton Phase II trials, July 31, 2003
Draxis divests Draxis Pharmaceutica, July 23, 2003
Copyright © 2004 AuntMinnie.com
